Compare GERN & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | PD |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.0M | 865.3M |
| IPO Year | 1996 | 2019 |
| Metric | GERN | PD |
|---|---|---|
| Price | $1.52 | $12.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $2.17 | ★ $12.63 |
| AVG Volume (30 Days) | ★ 10.8M | 1.2M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.85 | ★ 416.95 |
| EPS | N/A | ★ 0.13 |
| Revenue | $1,065,000.00 | ★ $492,546,000.00 |
| Revenue This Year | $26.91 | $3.58 |
| Revenue Next Year | $43.75 | $2.88 |
| P/E Ratio | ★ N/A | $93.23 |
| Revenue Growth | N/A | ★ 5.36 |
| 52 Week Low | $1.04 | $5.70 |
| 52 Week High | $2.01 | $17.29 |
| Indicator | GERN | PD |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 65.52 |
| Support Level | $1.42 | $10.89 |
| Resistance Level | $1.68 | $13.43 |
| Average True Range (ATR) | 0.10 | 0.49 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 58.82 | 88.92 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.